Search research articles
Contact Us
Filters
Showing results (171-180 of 212) with videos related to
Page
of 22
Sort By:
Blood
|
December 16, 2010
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma
Davide Rossi, Silvia Rasi, Alice Di Rocco, et al.
Cancer
|
May 27, 2003
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence
Corrado Tarella, Alessandra Cuttica, Umberto Vitolo, et al.
British Journal of Haematology
|
June 11, 2025
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)
Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, et al.
Iscience
|
April 25, 2025
Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma
Alessandra Rossi, Saveria Mazzara, Dorotea Salemi, et al.
Hemasphere
|
September 25, 2025
Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up
Catherine Thieblemont, Maria Gomes Da Silva, Sirpa Leppä, et al.
Blood
|
October 3, 2013
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program
Marco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, et al.
The Lancet. Haematology
|
December 9, 2016
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi
Carlo Visco, Annalisa Chiappella, Luca Nassi, et al.
The Lancet. Oncology
|
July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Annalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Ajay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.
Blood
|
February 2, 2008
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Marco Ladetto, Federica De Marco, Fabio Benedetti, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 212) with videos related to
Sort By:
Page
of 22
Blood
|
December 16, 2010
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma
Davide Rossi, Silvia Rasi, Alice Di Rocco, et al.
Cancer
|
May 27, 2003
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence
Corrado Tarella, Alessandra Cuttica, Umberto Vitolo, et al.
British Journal of Haematology
|
June 11, 2025
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL)
Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, et al.
Iscience
|
April 25, 2025
Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma
Alessandra Rossi, Saveria Mazzara, Dorotea Salemi, et al.
Hemasphere
|
September 25, 2025
Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up
Catherine Thieblemont, Maria Gomes Da Silva, Sirpa Leppä, et al.
Blood
|
October 3, 2013
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program
Marco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, et al.
The Lancet. Haematology
|
December 9, 2016
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi
Carlo Visco, Annalisa Chiappella, Luca Nassi, et al.
The Lancet. Oncology
|
July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Annalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Ajay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.
Blood
|
February 2, 2008
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Marco Ladetto, Federica De Marco, Fabio Benedetti, et al.
Page
of 22